Axatilimab plus steroids for new chronic GVHD
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old.
- You have new-onset moderate or severe chronic GVHD that needs treatment.
- You have had a stem cell transplant (from a related or unrelated donor).
- You have adequate blood counts (ANC ≥ 0.5) and are willing to avoid pregnancy.
- You have NOT received more than 7 days of steroids for your chronic GVHD, and no prior treatment for it (like photopheresis).
- You do NOT have active infections, relapse of your original disease, or serious heart, kidney, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
This trial tests an experimental drug called adrixetinib (Q702) for people with active chronic graft-versus-host disease that has not responded well to standard treatments. It aims to see if the drug can help control your symptoms when other options have stopped working.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.